 Connection
Jordana Hoppe to Child
This is a "connection" page, showing publications Jordana Hoppe has written about Child.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.603 |
|
|
|
-
Hoppe JE, Vigers T, Trujillo A, Hanley E, Sagel SD, Zemanick ET. Impact of Home Collection and Shipping of Respiratory Specimens on Bacterial Pathogen Detection in Children With Cystic Fibrosis. Pediatr Pulmonol. 2025 Sep; 60(9):e71289.
Score: 0.059
-
Hoppe JE, Kasi AS, Pittman JE, Jensen R, Thia LP, Robinson P, Tirakitsoontorn P, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Salinas DB, Zhu J, Chen YC, Rodriguez-Romero V, Sosnay PR, Davies G. Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial. Lancet Respir Med. 2025 Mar; 13(3):244-255.
Score: 0.056
-
Good A, Shannon J, Brinton JT, Hoppe JE. Implementation and outcomes of a quality improvement project to systematically assess the gross motor skills in school-aged children with cystic fibrosis. Pediatr Pulmonol. 2024 Oct; 59(10):2597-2605.
Score: 0.054
-
Jordan KD, Zemanick ET, Taylor-Cousar JL, Hoppe JE. Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor/tezacaftor/ivacaftor combination therapy. Expert Rev Respir Med. 2023 02; 17(2):97-108.
Score: 0.049
-
Hoppe JE, Zemanick ET, Martiniano SL. Evidence for Early Cystic Fibrosis Transmembrane Conductance Regulator Modulator Treatment for Children with Cystic Fibrosis Keeps Growing. Am J Respir Crit Care Med. 2022 12 01; 206(11):1308-1310.
Score: 0.049
-
Hoppe JE, Chilvers M, Ratjen F, McNamara JJ, Owen CA, Tian S, Zahigian R, Cornell AG, McColley SA. Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study. Lancet Respir Med. 2021 09; 9(9):977-988.
Score: 0.044
-
Hoppe JE, Hinds DM, Colborg A, Wagner BD, Morgan WJ, Rosenfeld M, Zemanick ET, Sanders DB. Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers. Pediatr Pulmonol. 2020 12; 55(12):3400-3406.
Score: 0.042
-
Hoppe JE, Sagel SD. Shifting Landscape of Airway Infection in Early Cystic Fibrosis. Am J Respir Crit Care Med. 2019 Sep 01; 200(5):528-529.
Score: 0.039
-
Hoppe JE, Wagner BD, Accurso FJ, Zemanick ET, Sagel SD. Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis. J Cyst Fibros. 2018 11; 17(6):760-768.
Score: 0.036
-
Muller PA, Mueller JL, Mellenthin M, Murthy R, Capps M, Wagner BD, Alsaker M, Deterding R, Sagel SD, Hoppe J. Evaluation of surrogate measures of pulmonary function derived from electrical impedance tomography data in children with cystic fibrosis. Physiol Meas. 2018 04 26; 39(4):045008.
Score: 0.035
-
Hoppe JE, Towler E, Wagner BD, Accurso FJ, Sagel SD, Zemanick ET. Sputum induction improves detection of pathogens in children with cystic fibrosis. Pediatr Pulmonol. 2015 Jul; 50(7):638-46.
Score: 0.028
-
Mayer-Hamblett N, Gifford AH, Kloster M, Russell R, Braun AT, Gibson RL, Hoppe JE, Jain R, Linnemann RW, Liou TG, Lysinger J, Milla C, Riekert KA, Sawicki GS, Young J, Nichols D. Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis. Ann Am Thorac Soc. 2024 Nov; 21(11):1507-1515.
Score: 0.014
-
Sanders DB, Bartz TM, Zemanick ET, Hoppe JE, Hinckley Stukovsky KD, Cogen JD, Bendy L, McNamara S, Enright E, Kime NA, Kronmal RA, Edwards TC, Morgan WJ, Rosenfeld M. A Pilot Randomized Clinical Trial of Pediatric Cystic Fibrosis Pulmonary Exacerbations Treatment Strategies. Ann Am Thorac Soc. 2023 12; 20(12):1769-1776.
Score: 0.013
-
Goralski JL, Hoppe JE, Mall MA, McColley SA, McKone E, Ramsey B, Rayment JH, Robinson P, Stehling F, Taylor-Cousar JL, Tullis E, Ahluwalia N, Chin A, Chu C, Lu M, Niu T, Weinstock T, Ratjen F, Rosenfeld M. Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele. Am J Respir Crit Care Med. 2023 07 01; 208(1):59-67.
Score: 0.013
-
Sagel SD, Kupfer O, Wagner BD, Davis SD, Dell SD, Ferkol TW, Hoppe JE, Rosenfeld M, Sullivan KM, Tiddens HAWM, Knowles MR, Leigh MW. Airway Inflammation in Children with Primary Ciliary Dyskinesia. Ann Am Thorac Soc. 2023 01; 20(1):67-74.
Score: 0.012
-
Lenhart-Pendergrass PM, Anthony M, Sariyska S, Andrews A, Scavezze H, Towler E, Martiniano SL, Hoppe JE, Zemanick ET. Detection of bacterial pathogens using home oropharyngeal swab collection in children with cystic fibrosis. Pediatr Pulmonol. 2021 07; 56(7):2043-2047.
Score: 0.011
-
Hoppe JE, Wahrenberger C. Compliance of pediatric patients with treatment involving antibiotic suspensions: a pilot study. Clin Ther. 1999 Jul; 21(7):1193-201.
Score: 0.010
-
Hoppe JE, von Einem C, Stern M. Evaluation of three methods for culturing alginate throat swabs from cystic fibrosis patients. Zentralbl Bakteriol. 1998 Dec; 288(4):457-61.
Score: 0.009
-
Hoppe JE, Holzwarth I, Stern M. Postal transport of sputa from cystic fibrosis patients does not decrease the microbiological yield. Zentralbl Bakteriol. 1997 Nov; 286(4):468-71.
Score: 0.009
-
Hoppe JE, Holzwarth J, Stern M. Comparison of four methods for pretreatment of cystic fibrosis sputa. Eur J Clin Microbiol Infect Dis. 1996 Nov; 15(11):895-6.
Score: 0.008
-
Hoppe JE, Theurer-Mainka U, Stern M. Comparison of three methods for culturing throat swabs from cystic fibrosis patients. J Clin Microbiol. 1995 Jul; 33(7):1896-8.
Score: 0.007
-
Hoppe JE, Köster S, Bootz F, Niethammer D. Acute mastoiditis--relevant once again. Infection. 1994 May-Jun; 22(3):178-82.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|